Rallybio Corp entered into a collaboration agreement with Johnson & Johnson to advance therapeutic solutions for pregnant individuals at risk of fetal and neonatal alloimmune thrombocytopenia (FNAIT), and also sold shares of common stock to Johnson & Johnson Innovation JJDC, Inc. in a private placement.